Peter J. Greasley

8.5k total citations · 4 hit papers
113 papers, 5.9k citations indexed

About

Peter J. Greasley is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Nephrology. According to data from OpenAlex, Peter J. Greasley has authored 113 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Endocrinology, Diabetes and Metabolism, 30 papers in Molecular Biology and 28 papers in Nephrology. Recurrent topics in Peter J. Greasley's work include Diabetes Treatment and Management (36 papers), Chronic Kidney Disease and Diabetes (23 papers) and Pancreatic function and diabetes (21 papers). Peter J. Greasley is often cited by papers focused on Diabetes Treatment and Management (36 papers), Chronic Kidney Disease and Diabetes (23 papers) and Pancreatic function and diabetes (21 papers). Peter J. Greasley collaborates with scholars based in Sweden, United Kingdom and United States. Peter J. Greasley's co-authors include Erik Ryberg, Thomas Elebring, Stephan Hjorth, Ruth A. Ross, Ken Mackie, Niklas Larsson, Peter Nilsson, Tomáš Drmota, S. Sjögren and Nils-Olov Hermansson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nucleic Acids Research.

In The Last Decade

Peter J. Greasley

107 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

2010 1.3k citations Roger G. Pertwee, Allyn C. Howlett et al. profile →
The orphan receptor GPR55 is a novel cannabinoid receptor

2007 1.2k citations Peter J. Greasley et al. profile →
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

2017 355 citations Peter J. Greasley, John J.V. McMurray et al. Diabetes Obesity and Metabolism profile →
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

2023 71 citations Hiddo J.L. Heerspink, Arihiro Kiyosue et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter J. Greasley Sweden	30	2.8k	1.6k	1.5k	1.5k	1.2k	113	5.9k
Michael Davidson United States	39	1.0k 0.4×	2.4k 1.5×	906 0.6×	373 0.3×	1.3k 1.1×	121	7.0k
Simon D Harding United Kingdom	24	770 0.3×	454 0.3×	2.9k 1.9×	1.2k 0.8×	634 0.5×	36	6.9k
Jonathan Z. Long United States	43	4.2k 1.5×	1.0k 0.6×	3.7k 2.4×	2.0k 1.3×	1.2k 1.1×	97	12.5k
Jean‐Pierre Maffrand France	36	1.3k 0.5×	570 0.4×	1.6k 1.0×	1.3k 0.9×	769 0.7×	90	5.8k
Robert C. Speth United States	44	861 0.3×	2.2k 1.4×	3.0k 2.0×	1.7k 1.1×	633 0.5×	218	7.7k
Luca Pani Italy	43	1.4k 0.5×	504 0.3×	1.9k 1.2×	1.9k 1.3×	325 0.3×	218	7.0k
Li Liu China	34	291 0.1×	808 0.5×	1.8k 1.2×	562 0.4×	512 0.4×	264	5.4k
Elizabeth H. Corder United States	28	1.1k 0.4×	667 0.4×	3.6k 2.4×	1.4k 0.9×	944 0.8×	59	11.3k
Elizabeth A. Thiele United States	52	2.8k 1.0×	467 0.3×	2.6k 1.7×	1.9k 1.3×	406 0.3×	198	12.1k
Yedy Israel Canada	51	442 0.2×	895 0.6×	2.6k 1.7×	1.9k 1.3×	442 0.4×	236	10.0k

Countries citing papers authored by Peter J. Greasley

Since Specialization

Citations

This map shows the geographic impact of Peter J. Greasley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Greasley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Greasley more than expected).

Fields of papers citing papers by Peter J. Greasley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Greasley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Greasley. The network helps show where Peter J. Greasley may publish in the future.

Co-authorship network of co-authors of Peter J. Greasley

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Greasley. A scholar is included among the top collaborators of Peter J. Greasley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Greasley. Peter J. Greasley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abood, Mary E., Christian C. Felder, Peter J. Greasley, et al.. (2025). Cannabinoid receptors in GtoPdb v.2025.1. IUPHAR/BPS Guide to Pharmacology CITE. 2025(1).

Jongs, Niels, Peter J. Greasley, Cecilia Karlsson, et al.. (2025). Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obesity and Metabolism. 27(8). 4415–4426. 1 indexed citations

Ambery, Phil, Peter J. Greasley, Robert Menzies, et al.. (2024). Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?. Clinical Science. 138(11). 687–697. 1 indexed citations

Hallow, K. Melissa, et al.. (2024). Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis. Frontiers in Pharmacology. 15. 1332388–1332388.

Greasley, Peter J., Nikhil Agrawal, Magnus Althage, et al.. (2024). #1003 Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of AZD2373, an antisense oligonucleotide targeting APOL1. Nephrology Dialysis Transplantation. 39(Supplement_1). 1 indexed citations

Veenit, Vandana, Hiddo J.L. Heerspink, Christine Ahlström, et al.. (2023). The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrology Dialysis Transplantation. 38(10). 2289–2297. 12 indexed citations

Abood, Mary E., S P H Alexander, Francis Barth, et al.. (2023). Cannabinoid receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023(1). 3 indexed citations

Carracedo, Miguel, Elke Ericson, Rasmus Ågren, et al.. (2023). APOL1 promotes endothelial cell activation beyond the glomerulus. iScience. 26(6). 106830–106830. 9 indexed citations

Yeoh, Su Ern, Kieran F. Docherty, Ross T. Campbell, et al.. (2023). Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 147(22). 1670–1683. 24 indexed citations

10.

Heerspink, Hiddo J.L., Arihiro Kiyosue, David C. Wheeler, et al.. (2023). Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. The Lancet. 402(10416). 2004–2017. 71 indexed citations breakdown →

11.

Heerspink, Hiddo J.L., Peter J. Greasley, Christine Ahlström, et al.. (2023). Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrology Dialysis Transplantation. 39(3). 414–425. 16 indexed citations

12.

Fisk, Marie, Magnus Althage, Sven Moosmang, et al.. (2021). Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology & Therapeutics. 69. 102035–102035. 10 indexed citations

13.

Muskiet, Marcel H.A., Anne C. Hesp, Peter J. Greasley, et al.. (2020). Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 44(2). 440–447. 87 indexed citations

14.

Stefánsson, Bergur V., Hiddo J.L. Heerspink, David C. Wheeler, et al.. (2020). Correction of anemia by dapagliflozin in patients with type 2 diabetes. Journal of Diabetes and its Complications. 34(12). 107729–107729. 32 indexed citations

15.

Abood, Mary E., S P H Alexander, Francis Barth, et al.. (2019). Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019(4). 12 indexed citations

16.

Greasley, Peter J.. (2011). Doing essays and assignments : essential tips for students. Lancaster EPrints (Lancaster University). 2 indexed citations

17.

Greasley, Peter J., et al.. (2009). High-Quality Cost-Effective Compound Management Support for HTS. SLAS DISCOVERY. 14(5). 509–514. 11 indexed citations

18.

Greasley, Peter J. & Neil Small. (2002). Primary care. Take it from here.. PubMed. 112(5795). 28–9. 2 indexed citations

19.

Greasley, Peter J., Francesca Fanelli, Alexander Scheer, et al.. (2001). Mutational and Computational Analysis of the α1b-Adrenergic Receptor. Journal of Biological Chemistry. 276(49). 46485–46494. 71 indexed citations

20.

Greasley, Peter J.. (2000). Handwriting analysis and personality assessment:the creative use of analogy, symbolism and metaphor. European Psychologist. 5(1). 44–51. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact